Multicellular life is tasked with the immensely complex process of clearing foreign and aberrant cells while preventing autoimmunity. This finely tuned balance is often mediated by enzymes involved in central metabolism, reflecting the ancient origin and strong selective pressure of immune regulation ([@r1]). Indoleamine 2,3-dioxygenase (IDO1) is one such enzyme that oxidizes the essential amino acid tryptophan to produce *N*-formylkynurenine, which is further hydrolyzed to kynurenine ([@r2], [@r3]). This enzyme is present in many tissues and is up-regulated in response to inflammation, specifically the presence of cytokines, such as IFN-γ, as well as bacterial lipopolysaccharides ([@r4], [@r5]). Cells expressing IDO1 are able to deplete the inflamed environment of the metabolically expensive substrate, tryptophan, inhibiting the proliferation of immune targets ([@r6], [@r7]).

IDO1 is also able to serve as an immunosuppressive enzyme. In a seminal paper, IDO1, which was known to be highly expressed in placental tissue, was shown to be essential for the protection of embryos from maternal immune responses. An IDO1 inhibitor, 1-methyl-tryptophan, caused rejection of fetuses capable of provoking the maternal immune response, whereas fetuses closely related to the mother, and thus less likely to provoke an immune response, survived ([@r8]). This remarkable ability of a single enzyme to mediate such complex immune behavior has since been studied in depth, revealing a rich variety of mechanisms by which this enzyme affects immune regulation.

Expression of IDO1 inactivates surrounding immune cells through the combined effects of low tryptophan and high concentrations of kynurenine ([@r1], [@r9]). T cells are especially sensitive to low tryptophan concentrations, where they undergo cell cycle arrest ([@r10]). Additionally, the downstream metabolites of the product of IDO1 are potent activators of the aryl hydrocarbon receptor through which apoptosis of immune cells can be initiated ([@r11]). IDO1 has further been shown to provide protection from oxidative stress caused by inflammatory processes ([@r12]).

The importance of IDO1 in precise immune regulation is highlighted by its effects in a variety of processes and disease states, including autoimmune disorders, response to infection, tolerance in transplantation, HIV infection, and blood pressure regulation ([@r13][@r14]--[@r15]). This regulation/dysregulation is perhaps most sinisterly manifested in cancer cells that co-opt the immunosuppressive ability of IDO1 to evade immune destruction ([@r16][@r17]--[@r18]). The transcriptional control of IDO1 in cancers is often altered through mutation of the Bin1 repressor that allows for vastly up-regulated levels of IDO1 ([@r19]). Tumors displaying high IDO1 activity are associated with poor prognoses ([@r20]). Accordingly, IDO1 is a prime target in the treatment of almost all cancers for which IDO1 inhibition could restore the ability of the immune system to remove these cancer cells on its own or in combination with other treatments ([@r17]). The immunosuppressive effects of IDO1 are also implicated in persistent bacterial infection, wherein IDO1 inhibition has been shown to aid in clearing the infection ([@r21]).

The mechanism of IDO1 proceeds through a sequential oxygen insertion reaction, where molecular oxygen binds to the ferrous heme and then adds across the C2-C3 double bond of tryptophan through an alkylperoxo intermediate to afford the epoxide with the second atom of molecular oxygen left on the heme in a ferryl compound II structure. This IDO1 ferryl is then proposed to attack the epoxide, breaking the oxygen--iron bond and reducing the iron back to the ferrous resting state ([@r22][@r23]--[@r24]). This surprising ferryl attack on an epoxide has not been fully explored, as it is not the rate-determining step, but it is consonant with the recent revelations of the reactivity and versatility of compound II in other enzymes ([@r25][@r26]--[@r27]).

Typical of other heme proteins, IDO1 is vulnerable to competitive inhibitors, such as substrate mimics or compounds with heme binding capabilities ([@r28][@r29][@r30]--[@r31]). This strategy, however, has suffered from a paucity of inhibitors capable of the specificity and nanomolar binding affinity desirable in a pharmaceutical ([@r32]). Exceptions to this long-standing paradigm have been reported recently that bind to the enzyme without binding directly to the heme iron ([@r33]). We report here an examination of the unique inhibitory modes of two classes of inhibitors that display favorable specificity and robust inhibition of IDO1 (HeLa cell IC~50~ = 4.2 and 0.50 nM for compounds **1** and **2**, respectively) ([*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)) ([@r34]).

Heme Cofactor of IDO1 Is Labile {#s1}
===============================

The mechanism of IDO1 inhibition by compounds **1** and **2** ([Fig. 1*A*](#fig01){ref-type="fig"}) was interrogated using activity assays with recombinant human IDO1. Compounds **1** and **2**, the latter currently being investigated in phase II clinical trials, are structurally disparate and lack any significant similarity to the substrate tryptophan or any obvious heme binding moieties that could explain their mode of action ([Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)). In both cases, these compounds showed an intriguingly slow onset of inhibition, which is inconsistent with a simple competitive mechanism ([Fig. 1*B*](#fig01){ref-type="fig"}). Both compounds also showed a clear temperature dependence, only prompting inhibition above 30 °C ([Fig. 1*C*](#fig01){ref-type="fig"} and [Fig. S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)).

![Time and temperature dependence of IDO1 inhibition. (*A*) Structure of three IDO1 inhibitors. (*B*) IDO1 (2.4 µM) was incubated with compounds **1** (20 µM), **2** (20 µM), or equine apomyoglobin (20 µM) at 37 °C for various times (*x* axis), after which this inhibition was tested using a standard activity assay (*y* axis). (*C*) IDO1 (2.4 µM) was incubated with compounds **1**, **2**, or equine apomyoglobin (20 µM) for 15 min at various temperatures (*x* axis), after which inhibition was tested using a standard activity assay following the rate of *N*-formylkynurenine production (*y* axis). Error bars represent SD. *N* ≥ 3.](pnas.1719190115fig01){#fig01}

As a test for IDO1 heme loss as the key initiatory step of inhibition, IDO1 was incubated with apo-myoglobin, which is capable of binding to free heme rapidly and essentially irreversibly, with a binding constant of 10^14^ M^−1^ ([@r35]). Remarkably, IDO1 with added apo-myoglobin was seen to lose activity, interpreted as heme loss to apo-myoglobin, with nearly the same time and temperature dependence as it does with **1** and **2** (*t*~1/2~ = 17, 14, and 11 min, respectively). This behavior is in contrast to the steadily maintained activity of IDO1 incubated in the absence of inhibitor or apo-myoglobin, indicating that heme binding to IDO1 is a dynamic, reversible process ([Fig. 1*B*](#fig01){ref-type="fig"}).

For a spectroscopic test of heme loss, IDO1 was incubated with a modified version of sperm whale apo-myoglobin, H64YV68F, that, when bound to heme, possesses a unique green color ([@r36]). IDO1 heme loss to apo-myoglobin can thus be conveniently monitored by an increase in absorbance at 600 nm. This confirmed that IDO1 readily loses its heme cofactor ([Fig. 2*A*](#fig02){ref-type="fig"} and [Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)) and that this unusual heme lability mirrors the temperature dependence of inhibition by **1** and **2** ([Fig. 2*B*](#fig02){ref-type="fig"}). In this way, IDO1 heme loss was shown to be inhibitor-independent and likely the shared rate-determining step of inhibition by **1** and **2**, accounting for the striking similarity of inhibitory profiles for these two distinct inhibitors.

![Transfer of heme from IDO1 to apomyoglobin. (*A*) The UV-visible spectra of heme transfer from IDO1 (5 µM) to apo-myoglobin H64YV68F (95 µM) over 40 min at 37 °C. (*B*) Heme dissociation from IDO1 (5 µM) to apo-myoglobin H64YV68F (95 µM) at various temperatures as indicated by the increase in absorbance at 600 nm.](pnas.1719190115fig02){#fig02}

1 and 2 Bind to IDO1 with Varying Off Rates {#s2}
===========================================

The mechanism by which these inhibitors exploit IDO1 heme lability was further explored using ^14^C-radiolabeled inhibitors in cold chase experiments. To test whether and how strongly these inhibitors bind to IDO1, the protein was incubated with ^14^C-labeled **1** and **2**. These incubations then had natural abundance versions of the inhibitors added, and at various times, the buffer and any unbound inhibitor were exchanged away from the protein using centrifugal concentrators. In this way, any residual inhibitor must be bound to IDO1 and can be quantified using its ^14^C radiation. This showed that IDO1 does bind to these compounds, but it does so with very large differences in off rate: *t*~1/2~ of 2 and 50 min for **1** and **2**, respectively ([Fig. 3](#fig03){ref-type="fig"}). This, despite nearly identical inhibition kinetics, strongly supports heme loss to be the shared and rate-determining step of inhibition.

![Cold chase experiments with radiolabeled inhibitors. Radiolabeled versions of **1** (*A*) and **2** (*B*) were incubated with IDO1 followed by introduction of natural abundance **1** and **2**, buffer exchange, and quantification of the residual, IDO1-bound, ^14^C-labeled **1** and **2**. Error bars represent SD. *N* = 2.](pnas.1719190115fig03){#fig03}

Inhibition Does Not Show a Linear Relationship with Inhibitor Concentration {#s3}
===========================================================================

The concentration dependence of inhibition by **1** and **2** was then examined to illuminate any differences that may indicate a binding event before heme loss. In incubations preceding activity assays, the concentrations of the inhibitors, including apo-myoglobin, were varied from 1 to 16 times that of IDO1, and despite these large differences, the rates of inhibition were nearly identical and certainly far from showing a linear relationship ([Fig. 4*A*](#fig04){ref-type="fig"}). These results show that apo-IDO1 formed from intrinsic heme loss is the target for these inhibitors, which must act in some way to block heme from rebinding.

![Concentration dependence of IDO1 inhibition. (*A*) IDO1 (2.4 µM) was incubated with various concentrations from 0 to 40 µM (*x* axis) of compounds **1**, **2**, or equine apomyoglobin at 37 °C, and for 15 min after, this inhibition was tested using a standard activity assay (*y* axis). (*B*) The experiment was repeated but with conditions that allow for turnover in the incubation with IDO1 before the activity assay. In this case, IDO1 (2.4 µM) was incubated with 2.4--40 µM **1**, **2**, or equine apomyoglobin at 37 °C for 15 min in the presence of 500 µM [l]{.smallcaps}-tryptophan, 10 mM ascorbate, 10 µM methylene blue, and 10 µg/mL catalase. The rate of *N*-formylkynurenine production was then tested using a standard activity assay (*y* axis). Error bars represent SD. *N* ≥ 3.](pnas.1719190115fig04){#fig04}

Inhibition Is Independent of IDO1 Turnover {#s4}
==========================================

This mechanism predicts that inhibition is independent of activity. To further confirm this hypothesis, we incubated IDO1 with various concentrations of inhibitor and the natural substrate, [l]{.smallcaps}-tryptophan. Activity was then assessed subsequently. As with all activity experiments described herein, [d]{.smallcaps}-tryptophan was used as the substrate, which unlike [l]{.smallcaps}-tryptophan, does not cause substrate inhibition and thus provides for a more convenient, repeatable means of determining activity ([@r37][@r38]--[@r39]). In these experiments, any [l]{.smallcaps}-tryptophan not converted to *N*-formylkynurenine will have been carried over from the incubations and acted as a substrate in addition to the 10 mM [d]{.smallcaps}-tryptophan (maximum final concentration of 15 μM [l]{.smallcaps}-tryptophan with a 33× dilution from incubation with inhibitor to activity assay solution). The inhibition profiles were nearly identical, regardless of turnover conditions during incubation with **1** and **2** ([Fig. 4*B*](#fig04){ref-type="fig"}). This observation confirms that the mechanism of inhibition is independent of turnover, supporting apo-IDO1 as the target for inhibition and its formation via heme dissociation as the rate-limiting step for this process.

Crystal Structures of IDO1--Inhibitor Complexes Reveal Their Mode of Action {#s5}
===========================================================================

The interaction of these inhibitors with IDO1 was clearly elucidated by X-ray crystallographic structures obtained from cocrystallization with **1** and **3**, the latter being a close analog of **2** ([Fig. 5](#fig05){ref-type="fig"}). (Compound **1** is BMS-978587, **2** is BMS-986205, and **3** is BMS-116.) Both inhibitors bound in a manner that displaced the heme cofactor, with each occupying different, although overlapping, space in the vacated heme pocket ([Figs. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental) and [S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)). Remarkably, the overall structure of IDO1 bound to each inhibitor was largely unperturbed compared with a heme-containing IDO1 structure (0.61 and 0.44 Å rmsd from 2D0T for cocrystal structures with **1** and **3**, respectively). The carboxylate of **1** forms a hydrogen bond with the backbone amide of Ala-264 and with His-346, which ordinarily coordinates with the heme iron on the proximal side. Binding of **1** also led to a shift in the flexible loop made of residues 260--265, an event previously observed with the binding of phenylimidazole ([@r40]). The loop shift revealed the putative substrate binding site to the distal face of heme, where the phenylurea group in **1** binds via edge-to-face π-interactions with Tyr-126 and hydrogen bonds with Ser-167. The quinoline of **3** occupies an additional pocket made available by side-chain rearrangements of Phe-270, Phe-214, His-346, and Arg-343 that are stabilized by edge-to-face π-interactions with Phe-270 and a hydrogen bond with Arg-343.

![Structure of IDO1--inhibitor complexes. (*A*) Superposition of the backbone atoms of the crystal structures of IDO1 holoenzyme (orange) over that of IDO1/**3** (blue). The overall structure of IDO1 undergoes little change on ligand binding. The loop corresponding to residues 260--265 is shifted, resulting in significant displacement (measured on Cα) of Ser-263 and Ala-264. Moreover, heme-coordinating residue His-346 is slightly rotated to interact with the ligand. (*B*) Sphere representation of **1** overlaid with heme shows that they bind IDO1 in a mutually exclusive manner. Binding geometries are shown for **1** in *C* and **3** in *D*. Structures were prepared from crystallographic coordinates using Maestro software to add hydrogens, determine protonation state of amino acid side chains, and minimize heavy atom deviation to a maximum of 0.3 Å from their crystallographic coordinates. Helix S (residues 383--399) is hidden in *C* and *D* for clarity. [Figs. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental) and [S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental) depict the pocket rendering of holo-IDO1 in comparison with inhibitor-bound structures ([Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)), the electron density maps of inhibitors **1** and **3** bound to apo-IDO1 ([Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)), and 2D ligand interaction maps for **1** and **3** ([Fig. S5](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)).](pnas.1719190115fig05){#fig05}

Apo-IDO1 Is Present in Cells {#s6}
============================

The physiological relevance of apo-IDO1 and its potential as a target for inhibition are supported by previous studies that have shown that IDO1 exists in the apo-form within cells and is capable of activation on addition of exogenous heme ([@r41]). To further support apo-IDO1 as the authentic target of **1** and **2**, additional cellular assays were performed under conditions in which IDO1 was overexpressed but heme concentrations were varied. Briefly, human ovarian cancer cells were treated with IFN-γ to induce IDO1 expression. The cells were then tested for IDO1 activity after addition of the ribosomal inhibitor cycloheximide to prevent interference from newly translated IDO1. Cellular IDO1 activity was then assessed after further incubation in the presence or absence of added heme. Despite evidence that IDO1 protein levels were similar ([Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)), the activity of those cells with added heme was approximately fivefold higher than that of cells not treated with additional heme, indicating that at least 85% of IDO1 exists in these cells in an apo-form that is capable of activation by exogenously added heme ([Fig. 6](#fig06){ref-type="fig"}). Thus, the target of these inhibitors as revealed in the crystal structures is confirmed to be not only physiologically relevant but also, the predominant form of this enzyme in these cells.

![Kynurenine production by human SKOV3 ovarian tumor cells. *Left* depicts results from cells stimulated for 24 h with IFN-γ in the absence of added hemin. *Right* depicts cells stimulated with IFN-γ in the presence of 40 µM hemin. Blue bars depict kynurenine production after 24 h of IFN-γ stimulation. Cells were washed for 1 h with fresh media containing cycloheximide to halt protein synthesis. Kynurenine production was measured 24 h after addition of fresh media devoid of heme (pink) or containing 40 µM hemin (dark blue). Error bars represent SD.](pnas.1719190115fig06){#fig06}

Having established that **1** and **2** compete with heme for apo-IDO1, it was of interest to determine the effect of added heme in the inhibition assays. When 40 µM heme was added to HeLa cells concurrently with stimulation of the cells with IFN-γ and inhibition was measured after 20 h of incubation, IC~50~ values were shifted less than twofold compared with the same experiment with no added heme (**1**, IC~50~ ± heme = 7.1/4.2 nM; **2**, IC~50~ ± heme = 1.1/0.5 nM). The lack of a dramatic heme-dependent potency shift for compound inhibition during the prolonged induction period could result from direct competition for newly synthesized apo-IDO1 between inhibitor and heme, whereby the higher affinity and/or slower off rate of the inhibitors compensate for the higher heme concentration.

Heme Lability Is Dependent on Redox State {#s7}
=========================================

The cellular results show that IDO1 heme loss is a major factor in its normal regulation. We found that IDO1 heme lability is strongly dependent on the redox status of iron in the heme cofactor. Using compound **2** to capture apo-IDO1 as it forms from heme loss, we found that ferrous IDO1, which is the resting state of the enzyme in its active form, binds at least 10-fold more tightly to heme than enzyme does in the ferric state, which is catalytically inactive ([Fig. 7](#fig07){ref-type="fig"} and [Fig. S7](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)). This was measured by fitting the loss in absorbance at the corresponding Soret maxima to a single exponential and comparing the half-lives. The kinetics of this loss show that this process is complex and may involve multiple states of heme binding, which will require additional study. The overall difference in heme retention, however, is significant.

![Redox state dependence of heme dissociation from IDO1. IDO1 (1.1 µM) was incubated for 40 min at 37 °C in the presence of 10 µM **2**. Heme dissociation from IDO1 was tracked by the loss of absorbance at the IDO1 λ~max~ of the Soret peak: 404 nm for ferric IDO1 and 425 nm for ferrous IDO1. (*A*) Spectra of ferric IDO1 at various times. *Inset* shows a comparison of the loss in absorbance for both ferric and ferrous IDO1 as a function of time. (*B*) Spectra of ferrous IDO1 at various times. IDO1 was reduced using 5 mM sodium dithionite in a nitrogen-flushed sealed cuvette, and the decay of dithionite can be seen by its decreasing absorption below 375 nm. *Inset* is a scheme showing inhibitor binding to IDO1 in place of heme, causing the observed reduction in absorbance.](pnas.1719190115fig07){#fig07}

A stretch of 20 amino acids missing from electron density of all IDO1 structures has been predicted to form a "closed" state on substrate binding, effectively blocking the solvent-exposed face of heme and introducing an intermolecular hydrogen bond with a heme propionate ([@r42]). It is, therefore, plausible that intracellular tryptophan concentrations also play a role in heme recruitment and retention in IDO1. We tested heme loss from IDO1 to apo-myoglobin H64YV68F in the presence of 0--10 mM [l]{.smallcaps}-tryptophan (the *K*~d~ of [l]{.smallcaps}-tryptophan and ferric IDO1 is reported to be 5.8 mM) and found that the rate of heme loss was seen to decrease with increasing substrate concentration ([Fig. S8](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental)) ([@r37]). This effect on ferric IDO1 may not be relevant, as intracellular concentrations of tryptophan are unlikely to approach this *K*~d~ ([@r43]); however, the *K*~d~ of ferrous IDO1 and [l]{.smallcaps}-tryptophan is significantly lower, 13 µM ([@r37]), and therefore, it is possible that tryptophan exerts this heme retention effect more strongly on the active, ferrous form of IDO1.

Discussion {#s8}
==========

The goal of effective and specific inhibition of IDO1 has been intensively pursued since the discovery that this enzyme is critical to cancer's evasion of immune responses ([@r17]). Whereas most inhibitors to date act as competitive inhibitors either by mimicking the substrate tryptophan or by binding to the heme cofactor ([@r28]), **1** and **2** are capable of inhibiting IDO1 by taking advantage of an entirely separate strategy of competing with the heme cofactor itself in binding to the apo-form of the enzyme ([Fig. 8](#fig08){ref-type="fig"}). In the effort to understand the mechanism of this inhibition, the importance of heme lability in IDO1 and its potential as a regulatory mechanism have been more fully revealed.

![Catalytic mechanism of tryptophan catabolism by IDO1 and its inhibition via heme dissociation.](pnas.1719190115fig08){#fig08}

The formation of such a large pool of apo-IDO1 is still not fully understood, although it has previously been shown that IDO2, a homolog of IDO1, is capable of down-regulating the activity of IDO1 through heme transfer and sequestration ([@r44]), and it is known that there is significant cross-talk between IDO1 and heme catabolism through heme oxygenase-1, leading to loss of IDO1 activity via heme starvation ([@r45]). It has also been shown that ferrous IDO1 can bind nitric oxide in the absence of tryptophan, inducing rupture of the heme iron-proximal histidine bond to form apo-IDO1 ([@r46]). This transformation bears similarity to the heme receptor of soluble guanylyl cyclase that, although it is part of a signaling process and is not catalytic, uses heme lability in its regulation and is a target for compounds capable of binding to its apo-form ([@r47], [@r48]).

We have here shown that heme lability is likely to play a significant role in posttranslational control of IDO1 activity in cells, and the fact that this lability is strongly dependent on the redox state of the heme provides a potential regulatory mechanism to control IDO1 activity. Raven and coworkers ([@r49]) have shown that IDO1 accumulates in the catalytically inactive ferric state during turnover when tryptophan concentrations are low in vitro, and IDO1 is capable of autoxidizing to the ferric state in vivo ([@r50]). Together, these data suggest that IDO1 is self-regulating; under low tryptophan conditions, activity can decrease immediately by conversion to the catalytically inactive ferric state from which it can proceed to the apo-form through heme loss ([Fig. 8](#fig08){ref-type="fig"}). Such a process would contribute to the large pool of apo-IDO1 that serves as the target for these inhibitors.

Additionally, the complexity seen in the heme loss kinetics, a fast phase followed by a slow phase evident in both assays of heme loss to apomyoglobin H64YV68F and heme loss in the presence of **2** ([Figs. 2](#fig02){ref-type="fig"} and [7](#fig07){ref-type="fig"}), suggests that a simple model of only holo- and apo-IDO1 may not fully encompass this heme loss phenomenon and that there may be intermediate states of heme binding that will require additional study.

In conclusion, we have shown that IDO1 readily loses heme in a dynamic, reversible, and oxidation state-dependent manner. Targeting the pool of apo-IDO1 provides a means by which a class of inhibitors is capable of effectively inhibiting IDO1 with the potential to restore normal immune clearing of cancerous cells. These results also reveal more fully the intricate metabolic control that can be achieved by modulating the affinity of IDO1 for its heme cofactor and suggest that many other such enzymes could be similarly regulated and mechanistically rich.

Materials and Methods {#s9}
=====================

Compounds **1**, **2**, and **3** were prepared at Bristol-Myers Squibb Co. by procedures described in published patent applications ([@r51], [@r52]). The ^14^C-radiolabeled versions of **1** and **2** were provided by Bristol-Myers Squibb Co.

Protein was expressed and purified using standard methods. Cell-free activity assays were performed using standard methods with an Agilent 8453 diode array spectrometer and temperature-controlled Fisher Scientific isotemp 1016s recirculating chiller. Cold chase experiments using ^14^C-radiolabeled **1** and **2** were performed as described in [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental). Crystallization conditions used to obtain inhibitor-bound and holo-IDO1 are described in [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental). Cell-based activity assays using HeLa and SKOV3 cells were performed as described in [*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719190115/-/DCSupplemental).
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